Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17747 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Giovanni Targher. Beteiligte Einrichtung: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Pyridazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
LINKED CONTENT This article is linked to Harrison et al paper. To view this article, visit https://doi.org/10.1111/apt.17734
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
- Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.
ORCID-Profile: Giovanni Targher
Zitieren
APA
Targher, G. (2024). Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17747
Vancouver
Targher G. Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17747
BibTeX
@article{Targher2024,
author = {Targher, Giovanni},
title = {Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17747}
}
EUVIMED